Sumitomo Pharma Co U/Adr (SMDPY) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

I am Toru Kimura, Representative Director and President of Sumitomo Pharma. Thank you for joining us today for the presentation of the financial results for Q2 of FY2025. I will then explain according to the materials. First, please go to page 3, the financial results for Q2 of FY2025 on a core basis. As you can see, revenue was 227.1 billion yen. Compared to the revised Q2 forecast announced in July, the increase is 20.1 billion yen. Compared to last year, this represents an increase of 46.4 billion yen. On the other hand, SG&A expenses and R&D expenses have been well controlled, with SG&A expenses down 4 billion yen and R&D expenses down 4.5 billion yen from the figures announced in July. Compared to the previous fiscal year, the amount of these items was 9.5 billion yen and 7.6 billion yen respectively, which is well controlled. Since we have recorded a 49 billion yen gain on the transfer of the China-Asia business, the total core operating profit is 96.1 billion yen. This is an increase of 26.1 billion yen compared to the projected figure in July. Operating profit was 96.2 billion yen, followed by a reversal of deferred income tax liability for income tax expenses of 6.1 billion yen, resulting in an interim net profit of 98.9 billion yen. This is a 42.9 billion yen increase. Both sales and profit were over the Q2 forecast announced in July, and we are issuing a press release today to announce the revised forecast. I would like to continue with an overview of Q2 financial results. I will first explain the revenue of our main products, starting with the figures for North America. Orgovix is doing very well with 69.1 billion yen. This is an increase of 33.6 billion yen over last year. or 95%. Jemtesa is also 43.4 billion yen, which is an increase of 18.1 billion yen...